Dendreon Corporation, a biotechnology company specializing in cancer-fighting pharmaceuticals, will locate a $70 million manufacturing facility in Union City, Georgia, according to the Georgia governor's office. The company plans to build a 160,000-square-foot plant to manufacture Provenge, a drug for advanced prostate cancer that is currently under review by the U.S. Food and Drug Administration (FDA); pending Provenge's approval, the manufacturing plant could generate several hundred new jobs in the region. Washington-headquartered Dendreon develops therapies for cancer treatment that focus on strengthening the immune system. "We have particularly enjoyed partnering with the state of Georgia, Fulton County officials, and the local community during this process, and are grateful for their partnership and support as we prepare to commercialize Provenge to help the many patients with advanced prostate cancer who currently have few appealing treatment options." State officials did not release specific information regarding financial incentives.